{"id":251067,"date":"2025-03-11T00:00:00","date_gmt":"2025-03-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidmd0029-biopharma-type-2-diabetes-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:26:46","modified_gmt":"2026-03-31T10:26:46","slug":"epidmd0029-biopharma-type-2-diabetes-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0029-biopharma-type-2-diabetes-epidemiology-mature-markets\/","title":{"rendered":"Type 2 Diabetes &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of type 2 diabetes (<abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"type 2 diabetes\">T2D<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"type 2 diabetes\">T2D<\/abbr>, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"type 2 diabetes\">T2D<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"type 2 diabetes\">T2D<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of <abbr title=\"type 2 diabetes\">T2D<\/abbr> cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of <abbr title=\"type 2 diabetes\">T2D<\/abbr> by diagnosis status.<\/li>\n<li>Total prevalent cases of <abbr title=\"type 2 diabetes\">T2D<\/abbr> by body mass index.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> by glycemic control status.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> with <abbr data-abbreviation-entity=\"5027\" title=\"cardiovascular disease\">CVD<\/abbr> by drug-treatment status.<\/li>\n<li>Drug-treated prevalent cases of <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> by glycemic control status.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251067","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251067\/revisions"}],"predecessor-version":[{"id":571930,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251067\/revisions\/571930"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}